Hospital and Nursing Home Probiotic Market

ID: MRFR/FnB/30179-HCR
128 Pages
Varsha More
Last Updated: July 23, 2026
Hospital and Nursing Home Probiotic Market Size, Share, Industry Trend & Analysis Research Report By Probiotic Formulation Type (Capsules, Powder, Liquid, Soft Chew, Probiotic Yogurt), By Target Patient Group (Infants, Adults, Elderly, Immunocompromised Patients, Patients with Gastrointestinal Disorders), By Indication (Antibiotic-Associated Diarrhea, Irritable Bowel Syndrome, Clostridium difficile Infection, Inflammatory Bowel Disease, General Gut Health), By Distribution Channel (Hospitals, Nursing Homes, Pharmacies, Online Retail, Healthcare Facilities), By Product Source (Bacterial Strains, Yeast Strains, Synbiotics, Fermented Foods) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035.
Hospital and Nursing Home Probiotic Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.52%
2024 Market Size$ 2.94 Billion
2025 Market Size$ 3.19 Billion
2035 Market Size$ 7.23 Billion
Key Players
Danone
Nestle
Procter & Gamble
Kerry Group
Chr. Hansen
Lactalis Ingredients
Trends
  • Rising Awareness of Gut Health
  • Personalized Probiotic Solutions
  • Research and Development Advancements
Opportunities
  • Growing Focus on Preventive Healthcare
  • Regulatory Support for Probiotic Products
  • Increasing Incidence of Digestive Disorders
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Food, Beverages & Nutrition, BY Probiotic Formulation Type (USD Billion) | |
      1. 4.1.1 Capsules | |
      2. 4.1.2 Powder | |
      3. 4.1.3 Liquid | |
      4. 4.1.4 Soft Chew | |
      5. 4.1.5 Probiotic Yogurt |
    2. 4.2 Food, Beverages & Nutrition, BY Target Patient Group (USD Billion) | |
      1. 4.2.1 Infants | |
      2. 4.2.2 Adults | |
      3. 4.2.3 Elderly | |
      4. 4.2.4 Immunocompromised Patients | |
      5. 4.2.5 Patients with Gastrointestinal Disorders |
    3. 4.3 Food, Beverages & Nutrition, BY Indication (USD Billion) | |
      1. 4.3.1 Antibiotic-Associated Diarrhea | |
      2. 4.3.2 Irritable Bowel Syndrome | |
      3. 4.3.3 Clostridium difficile Infection | |
      4. 4.3.4 Inflammatory Bowel Disease | |
      5. 4.3.5 General Gut Health |
    4. 4.4 Food, Beverages & Nutrition, BY Distribution Channel (USD Billion) | |
      1. 4.4.1 Hospitals | |
      2. 4.4.2 Nursing Homes | |
      3. 4.4.3 Pharmacies | |
      4. 4.4.4 Online Retail | |
      5. 4.4.5 Healthcare Facilities |
    5. 4.5 Food, Beverages & Nutrition, BY Product Source (USD Billion) | |
      1. 4.5.1 Bacterial Strains | |
      2. 4.5.2 Yeast Strains | |
      3. 4.5.3 Synbiotics | |
      4. 4.5.4 Fermented Foods |
    6. 4.6 Food, Beverages & Nutrition, BY Region (USD Billion) | |
      1. 4.6.1 North America | | |
        1. 4.6.1.1 US | | |
        2. 4.6.1.2 Canada | |
      2. 4.6.2 Europe | | |
        1. 4.6.2.1 Germany | | |
        2. 4.6.2.2 UK | | |
        3. 4.6.2.3 France | | |
        4. 4.6.2.4 Russia | | |
        5. 4.6.2.5 Italy | | |
        6. 4.6.2.6 Spain | | |
        7. 4.6.2.7 Rest of Europe | |
      3. 4.6.3 APAC | | |
        1. 4.6.3.1 China | | |
        2. 4.6.3.2 India | | |
        3. 4.6.3.3 Japan | | |
        4. 4.6.3.4 South Korea | | |
        5. 4.6.3.5 Malaysia | | |
        6. 4.6.3.6 Thailand | | |
        7. 4.6.3.7 Indonesia | | |
        8. 4.6.3.8 Rest of APAC | |
      4. 4.6.4 South America | | |
        1. 4.6.4.1 Brazil | | |
        2. 4.6.4.2 Mexico | | |
        3. 4.6.4.3 Argentina | | |
        4. 4.6.4.4 Rest of South America | |
      5. 4.6.5 MEA | | |
        1. 4.6.5.1 GCC Countries | | |
        2. 4.6.5.2 South Africa | | |
        3. 4.6.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Danone (FR) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Nestle (CH) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Procter & Gamble (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Kerry Group (IE) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Chr. Hansen (DK) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Lactalis Ingredients (FR) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Synlogic (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 BioCare Copenhagen (DK) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 ProbioFerm (DE) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    7. 6.4 US MARKET ANALYSIS BY TARGET PATIENT GROUP |
    8. 6.5 US MARKET ANALYSIS BY INDICATION |
    9. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    10. 6.7 US MARKET ANALYSIS BY PRODUCT SOURCE |
    11. 6.8 CANADA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    13. 6.10 CANADA MARKET ANALYSIS BY INDICATION |
    14. 6.11 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    15. 6.12 CANADA MARKET ANALYSIS BY PRODUCT SOURCE |
    16. 6.13 EUROPE MARKET ANALYSIS |
    17. 6.14 GERMANY MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    18. 6.15 GERMANY MARKET ANALYSIS BY TARGET PATIENT GROUP |
    19. 6.16 GERMANY MARKET ANALYSIS BY INDICATION |
    20. 6.17 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    21. 6.18 GERMANY MARKET ANALYSIS BY PRODUCT SOURCE |
    22. 6.19 UK MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    23. 6.20 UK MARKET ANALYSIS BY TARGET PATIENT GROUP |
    24. 6.21 UK MARKET ANALYSIS BY INDICATION |
    25. 6.22 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    26. 6.23 UK MARKET ANALYSIS BY PRODUCT SOURCE |
    27. 6.24 FRANCE MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    28. 6.25 FRANCE MARKET ANALYSIS BY TARGET PATIENT GROUP |
    29. 6.26 FRANCE MARKET ANALYSIS BY INDICATION |
    30. 6.27 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    31. 6.28 FRANCE MARKET ANALYSIS BY PRODUCT SOURCE |
    32. 6.29 RUSSIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    33. 6.30 RUSSIA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    34. 6.31 RUSSIA MARKET ANALYSIS BY INDICATION |
    35. 6.32 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    36. 6.33 RUSSIA MARKET ANALYSIS BY PRODUCT SOURCE |
    37. 6.34 ITALY MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    38. 6.35 ITALY MARKET ANALYSIS BY TARGET PATIENT GROUP |
    39. 6.36 ITALY MARKET ANALYSIS BY INDICATION |
    40. 6.37 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    41. 6.38 ITALY MARKET ANALYSIS BY PRODUCT SOURCE |
    42. 6.39 SPAIN MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    43. 6.40 SPAIN MARKET ANALYSIS BY TARGET PATIENT GROUP |
    44. 6.41 SPAIN MARKET ANALYSIS BY INDICATION |
    45. 6.42 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    46. 6.43 SPAIN MARKET ANALYSIS BY PRODUCT SOURCE |
    47. 6.44 REST OF EUROPE MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    48. 6.45 REST OF EUROPE MARKET ANALYSIS BY TARGET PATIENT GROUP |
    49. 6.46 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
    50. 6.47 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    51. 6.48 REST OF EUROPE MARKET ANALYSIS BY PRODUCT SOURCE |
    52. 6.49 APAC MARKET ANALYSIS |
    53. 6.50 CHINA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    54. 6.51 CHINA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    55. 6.52 CHINA MARKET ANALYSIS BY INDICATION |
    56. 6.53 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    57. 6.54 CHINA MARKET ANALYSIS BY PRODUCT SOURCE |
    58. 6.55 INDIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    59. 6.56 INDIA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    60. 6.57 INDIA MARKET ANALYSIS BY INDICATION |
    61. 6.58 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    62. 6.59 INDIA MARKET ANALYSIS BY PRODUCT SOURCE |
    63. 6.60 JAPAN MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    64. 6.61 JAPAN MARKET ANALYSIS BY TARGET PATIENT GROUP |
    65. 6.62 JAPAN MARKET ANALYSIS BY INDICATION |
    66. 6.63 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    67. 6.64 JAPAN MARKET ANALYSIS BY PRODUCT SOURCE |
    68. 6.65 SOUTH KOREA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    69. 6.66 SOUTH KOREA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    70. 6.67 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
    71. 6.68 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    72. 6.69 SOUTH KOREA MARKET ANALYSIS BY PRODUCT SOURCE |
    73. 6.70 MALAYSIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    74. 6.71 MALAYSIA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    75. 6.72 MALAYSIA MARKET ANALYSIS BY INDICATION |
    76. 6.73 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    77. 6.74 MALAYSIA MARKET ANALYSIS BY PRODUCT SOURCE |
    78. 6.75 THAILAND MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    79. 6.76 THAILAND MARKET ANALYSIS BY TARGET PATIENT GROUP |
    80. 6.77 THAILAND MARKET ANALYSIS BY INDICATION |
    81. 6.78 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    82. 6.79 THAILAND MARKET ANALYSIS BY PRODUCT SOURCE |
    83. 6.80 INDONESIA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    84. 6.81 INDONESIA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    85. 6.82 INDONESIA MARKET ANALYSIS BY INDICATION |
    86. 6.83 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    87. 6.84 INDONESIA MARKET ANALYSIS BY PRODUCT SOURCE |
    88. 6.85 REST OF APAC MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    89. 6.86 REST OF APAC MARKET ANALYSIS BY TARGET PATIENT GROUP |
    90. 6.87 REST OF APAC MARKET ANALYSIS BY INDICATION |
    91. 6.88 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    92. 6.89 REST OF APAC MARKET ANALYSIS BY PRODUCT SOURCE |
    93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
    94. 6.91 BRAZIL MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    95. 6.92 BRAZIL MARKET ANALYSIS BY TARGET PATIENT GROUP |
    96. 6.93 BRAZIL MARKET ANALYSIS BY INDICATION |
    97. 6.94 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    98. 6.95 BRAZIL MARKET ANALYSIS BY PRODUCT SOURCE |
    99. 6.96 MEXICO MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    100. 6.97 MEXICO MARKET ANALYSIS BY TARGET PATIENT GROUP |
    101. 6.98 MEXICO MARKET ANALYSIS BY INDICATION |
    102. 6.99 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    103. 6.100 MEXICO MARKET ANALYSIS BY PRODUCT SOURCE |
    104. 6.101 ARGENTINA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    105. 6.102 ARGENTINA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    106. 6.103 ARGENTINA MARKET ANALYSIS BY INDICATION |
    107. 6.104 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    108. 6.105 ARGENTINA MARKET ANALYSIS BY PRODUCT SOURCE |
    109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
    112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT SOURCE |
    114. 6.111 MEA MARKET ANALYSIS |
    115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY TARGET PATIENT GROUP |
    117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
    118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT SOURCE |
    120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
    123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT SOURCE |
    125. 6.122 REST OF MEA MARKET ANALYSIS BY PROBIOTIC FORMULATION TYPE |
    126. 6.123 REST OF MEA MARKET ANALYSIS BY TARGET PATIENT GROUP |
    127. 6.124 REST OF MEA MARKET ANALYSIS BY INDICATION |
    128. 6.125 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL |
    129. 6.126 REST OF MEA MARKET ANALYSIS BY PRODUCT SOURCE |
    130. 6.127 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION |
    131. 6.128 RESEARCH PROCESS OF MRFR |
    132. 6.129 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION |
    133. 6.130 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION |
    134. 6.131 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION |
    135. 6.132 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION |
    136. 6.133 FOOD, BEVERAGES & NUTRITION, BY PROBIOTIC FORMULATION TYPE, 2024 (% SHARE) |
    137. 6.134 FOOD, BEVERAGES & NUTRITION, BY PROBIOTIC FORMULATION TYPE, 2024 TO 2035 (USD Billion) |
    138. 6.135 FOOD, BEVERAGES & NUTRITION, BY TARGET PATIENT GROUP, 2024 (% SHARE) |
    139. 6.136 FOOD, BEVERAGES & NUTRITION, BY TARGET PATIENT GROUP, 2024 TO 2035 (USD Billion) |
    140. 6.137 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 (% SHARE) |
    141. 6.138 FOOD, BEVERAGES & NUTRITION, BY INDICATION, 2024 TO 2035 (USD Billion) |
    142. 6.139 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 (% SHARE) |
    143. 6.140 FOOD, BEVERAGES & NUTRITION, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion) |
    144. 6.141 FOOD, BEVERAGES & NUTRITION, BY PRODUCT SOURCE, 2024 (% SHARE) |
    145. 6.142 FOOD, BEVERAGES & NUTRITION, BY PRODUCT SOURCE, 2024 TO 2035 (USD Billion) |
    146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    147. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.2.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.3.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.4.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.5.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.6.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.7.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.8.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.9.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.10.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.11.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.12.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.13.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.14.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.15.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.16.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.17.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.18.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.19.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.20.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.21.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.22.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.23.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.24.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.25.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.26.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.27.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.28.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.29.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY PROBIOTIC FORMULATION TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY TARGET PATIENT GROUP, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY INDICATION, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion) | |
      5. 7.30.5 BY PRODUCT SOURCE, 2025-2035 (USD Billion) |
    177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    178. 7.32 ACQUISITION/PARTNERSHIP | |

Hospital and Nursing Home Probiotic Market Segmentation

Hospital and Nursing Home Probiotic Market By Probiotic Formulation Type (USD Billion, 2025-2035)

  • Capsules
  • Powder
  • Liquid
  • Soft Chew
  • Probiotic Yogurt

Hospital and Nursing Home Probiotic Market By Target Patient Group (USD Billion, 2025-2035)

  • Infants
  • Adults
  • Elderly
  • Immunocompromised Patients
  • Patients with Gastrointestinal Disorders

Hospital and Nursing Home Probiotic Market By Indication (USD Billion, 2025-2035)

  • Antibiotic-Associated Diarrhea
  • Irritable Bowel Syndrome
  • Clostridium difficile Infection
  • Inflammatory Bowel Disease
  • General Gut Health

Hospital and Nursing Home Probiotic Market By Distribution Channel (USD Billion, 2025-2035)

  • Hospitals
  • Nursing Homes
  • Pharmacies
  • Online Retail
  • Hospital and Nursing Home Probiotic Market Facilities

Hospital and Nursing Home Probiotic Market By Product Source (USD Billion, 2025-2035)

  • Bacterial Strains
  • Yeast Strains
  • Synbiotics
  • Fermented Foods

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.